MAP3K7/TAK1

Mitogen-activated protein kinase kinase kinase 7 (MAP3K7, also known as TAK1) is a serine/threonine kinase that functions as a central signaling hub integrating inputs from TGF-β, IL-1, and Wnt pathways^[1][2]. TAK1 regulates key downstream signaling cascades including NF-κB, JNK, and p38 MAPK, thereby controlling cellular processes such as survival, proliferation, and differentiation^[1][3][4][2]. Mechanistically, TAK1 activation requires interaction with binding partners TAB1 and TAB2/TAB3, and is modulated by phosphorylation and ubiquitination at key residues such as Lys562, which enables differential MAPK and IKK activation. Compared with related MAP3K isoforms, TAK1 exhibits tissue- and cell type-specific functions, including negative regulation of NF-κB and p38 MAPK in neutrophils, while promoting hematopoietic stem cell maintenance through TNF-dependent and independent mechanisms^[3][5][6]. In developmental contexts, TAK1 enhances cardiogenic endoderm differentiation from mouse embryonic stem cells and regulates adipocyte commitment via BMP-PPARγ signaling^[7][8]. Pathologically, MAP3K7 mutations or deletions are implicated in pediatric T-ALL, frontometaphyseal dysplasia, cardiospondylocarpofacial syndrome, and liver carcinogenesis, demonstrating its relevance in both hematologic and solid tissue disease models^[9][10][11]. Pharmacologically, TAK1 can be selectively inhibited by type II small molecule inhibitors, such as NG25, which stabilize the DFG-out kinase conformation, enabling experimental modulation of its signaling for therapeutic applications^[12][13].